Clinical trials: SARS-CoV-2 Infection
Covid19, Sepsis
Feasibility Study of Hematology Parameters in COVID-19 Disease
The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or…
- Conditions
- Covid19, Sepsis, Adults, Emergency Department
- Trial name
- NCT04816630
- Testing
- CBC-Diff Monocyte Volume Width Distribution
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Beckman Coulter, Inc.
Coronavirus Disease 2019
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (> 12 weeks) of COVID-19.
- Trial name
- NCT04678830
- Testing
- Leronlimab (700mg)
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- CytoDyn, Inc.
COVID - 19
A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19
A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.
- Trial name
- NCT04834128
- Testing
- TCB008
- Where
- United Kingdom
- Sponsor
- TC Biopharm
COVID-19
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
This is a retrospective test-negative case-control study of COVID-19 Vaccine (CoronaVac®) manufactured by Sinovac Research and Development Co., Ltd.The main purpose of this study is to measure vaccine effectiveness of homologous…
- Trial name
- NCT05367895
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Brazil
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Corona Virus Infection
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
To evaluate the safety and tolerability, the antiviral activity, and plasma pharmacokinetics (PK) of zotatifin administered intravenously (IV) to adults with mild or moderate COVID-19.
- Trial name
- PROPEL (NCT04632381)
- Testing
- Zotatifin
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Effector Therapeutics
Covid19, Coronavirus
SPI-1005 Treatment in Severe COVID-19 Patients
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19…
- Conditions
- Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
- Trial name
- NCT04483973
- Testing
- Ebselen
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
COVID-19
A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19
The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison with SOC alone in hospitalized COVID-19…
- Trial name
- NCT04460183
- Testing
- RESP301, a Nitric Oxide generating solution, Standard of Care
- Where
- 2 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Thirty Respiratory Limited
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers. 1.
- Trial name
- COVSP-BCG (NCT03305341)
- Testing
- COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults
This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
- Trial name
- STORM CHASER (NCT04625972)
- Testing
- AZD7442
- Where
- 57 sites in United States, United Kingdom
- Volunteers
- 1,131 people
- Sponsor
- AstraZeneca
Covid19, Community-Acquired Respiratory Tract Infection
Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19
Solving the problem of detecting asymptomatic carriers who can transmit infection is key to protecting vulnerable residents of nursing homes and assisted living facilities, to protecting frontline workers who care for them, and…
- Trial name
- NCT04548895
- Testing
- Observational measurement of biometric data. No change to health care provided.
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Health Stream Analytics, LLC
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-US-O (NCT04426201)
- Testing
- CYT107
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Revimmune
Long COVID, COVID-19 (SARS-CoV-2 Infection)
Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome
This Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept study is being conducted to investigate the safety (whether there are any side effects), tolerability (if it does cause side effects, how well your…
- Conditions
- Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine, COVID Long
- Trial name
- FLINTLOCK (NCT07899346)
- Testing
- VYD2311
- Volunteers
- 130 people
- Sponsor
- Invivyd, Inc.
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205083
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19, COVID
Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test
The Metrix COVID Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Trial name
- NCT06744660
- Testing
- Aptitude Medical Systems Metrix COVID Test
- Where
- United States
- Volunteers
- 697 people, healthy volunteers welcome
- Sponsor
- Aptitude Medical Systems
Acute Respiratory Distress Syndrome, COVID-19
Predictors of Severe COVID-19 Outcomes
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes…
- Trial name
- PRESCO (NCT04388813)
- Where
- 8 sites in United States
- Volunteers
- 494 people
- Sponsor
- Verily Life Sciences LLC
SARS-CoV-2
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver solid organ transplant (SOT)…
- Trial name
- NCT04860297
- Testing
- mRNA-1273
- Where
- 15 sites in United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19.
- Trial name
- NCT04705597
- Testing
- BGE-175
- Where
- 26 sites in United States, Argentina and 1 more
- Volunteers
- 194 people
- Sponsor
- BioAge Labs, Inc.
COVID-19
Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine…
- Trial name
- NCT04526990
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 74 sites in Argentina, Chile and 3 more
- Volunteers
- 44,247 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Influenza, SARS-CoV-2
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65…
- Trial name
- NCT06508320
- Testing
- mRNA-1083
- Where
- 17 sites in United States, Canada
- Volunteers
- 931 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.